Natixis Advisors LLC Has $5.14 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Natixis Advisors LLC cut its stake in Glaukos Co. (NYSE:GKOS) by 9.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 34,299 shares of the medical instruments supplier’s stock after selling 3,439 shares during the quarter. Natixis Advisors LLC’s holdings in Glaukos were worth $5,143,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GKOS. IFP Advisors Inc acquired a new position in Glaukos in the 4th quarter valued at $43,000. Asset Planning Inc acquired a new position in Glaukos in the 4th quarter valued at $90,000. Harvest Fund Management Co. Ltd raised its holdings in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 860 shares in the last quarter. Picton Mahoney Asset Management acquired a new position in Glaukos in the 4th quarter valued at $125,000. Finally, SBI Securities Co. Ltd. acquired a new position in Glaukos in the 4th quarter valued at $153,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GKOS shares. Stephens raised Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus boosted their price target on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. BTIG Research boosted their price target on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Truist Financial boosted their price target on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler reissued an “overweight” rating and set a $180.00 price target (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $163.25.

Glaukos Trading Up 1.4 %

Shares of GKOS stock opened at $102.02 on Friday. The firm has a market capitalization of $5.77 billion, a P/E ratio of -35.55 and a beta of 0.99. Glaukos Co. has a twelve month low of $87.31 and a twelve month high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock’s fifty day simple moving average is $135.32 and its 200 day simple moving average is $136.53.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. As a group, sell-side analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.